Congressman Questions Pershing Square’s Planned Allergan Referendum

May 29 2014 | 9:58am ET

A California congressman has waded into the battle between Valeant Pharmaceuticals and Allergan Inc., asked federal regulators to look into Pershing Square Capital Management’s planned shareholder referendum on the latter’s bid for the former.

Rep. Edward Royce (R-Calif.) warned that the unusual effort taking place outside of Allergan’s standard proxy process “could make it difficult for shareholders to truly understand what is occurring.”

Pershing Square has filed for a non-binding shareholder referendum on Valeant’s offer for Allergan, which Valeant increased yesterday. The hedge fund is Allergan’s largest shareholder and is working with Valeant on the deal.

“This is the first shadow shareholder referendum of its kind filed at the” Securities and Exchange Commission, “and it’s at the expense of shareholder transparency,” Royce wrote the SEC Chairman Mary Jo White. “My immediate concern is that the SEC performs a thorough review of the details of this filing with that transparency in mid. Allergan’s investors and the U.S. capital markets deserve nothing less.”

Allergan is based in Irvine, Calif., just south of Royce’s district, and the company’s political action committee has donated $5,000 to Royce’s reelection campaign.

Pershing Square founder William Ackman rejected Royce’s concerns, telling The Wall Street Journal “there is nothing more transparent than a vote of the shareholders under the SEC’s proxy rules.” Valeant CEO Michael Pearson chided Allergan, which has rejected the offer and blasted Valeant’s business model, for “spending an awful lot of time trying to get [the shareholder vote] outlawed and not happen.”


In Depth

Kettera Q&A: The Advantages of Alternative Investment Platforms

Oct 28 2016 | 5:52pm ET

The past several years have seen a distinct push towards easier and cheaper access...

Lifestyle

Midtown's Plaza District Fades As Manhattan Office Landscape Shifts

Nov 22 2016 | 6:32pm ET

Lower leasing costs, more efficient office space and the hope of projecting an image...

Guest Contributor

Nowhere to Hide: Why the Future of Asset Management Depends on Innovation

Nov 15 2016 | 6:55pm ET

Information technology has reshaped the asset management industry’s periphery,...

 

From the current issue of

Chicago-based independent futures brokerage and clearing firm R.J. O’Brien & Associates (RJO) has hired industry veteran Daniel Staniford as Executive Director, responsible for the firm’s institutional business development in New York and London.

AVAILABLE NOW at BARNES & NOBLE

NEWSTAND LOCATOR